Bristol Myers Squibb invests in Dragonfly Therapeutics, a company co-founded by IVRI faculty director, David Raulet

Recent Posts

IVRI Faculty director publishes new potential target for immunotherapy – The activation of the adaptor protein STING depends on its interactions with the phospholipid PI4P
UC Berkeley Assistant Professor in Immunology Michel DuPage published in Cancer Immunology – Separating the Good from the Bad: Tumor-Infiltrating Tregs Have Increased Fucosylation
IVRI faculty director David Raulet and collaborators, reviewed in Nature Reviews Immunology, why Natural killer (NK) cells are emerging as important new additions to the cancer therapeutic arsenal.
David Raulet’s research addresses how the immune system recognizes and responds to cancer cells and virus-infected cells. Recognized with many awards for his scientific contributions, Raulet was elected to the National Academy of Sciences in 2019 and is a Distinguished Fellow of the American Association of Immunologists.
Berkeley Students fighting Cancer – Student Technology Fund supports Drug Discovery summer Workshop at CEND –

Recent Comments

Archives

March 2024
November 2023
June 2022
May 2022
August 2021
October 2020
September 2020
July 2020
June 2020
May 2020
March 2020
December 2019
October 2019
September 2019
August 2019
April 2019
February 2019
January 2019
November 2018
October 2018
June 2018
May 2018
March 2018
January 2018
December 2017
November 2017
October 2017
March 2017

Categories

Event
News
Perspective
Publication

Meta

Log in
Entries feed
Comments feed
WordPress.org